How is Muscular Dystrophy Diagnosed? 7 Key Assessment Methods

Muscular dystrophy (MD) is not a single condition – it is a group of more than 30 genetic disorders that cause progressive muscle weakness and degeneration. Because different types manifest at different ages and in different ways, getting a confirmed diagnosis can take time. Yet early and accurate diagnosis matters enormously. While there is no cure, starting the right interventions early can slow disease progression, prevent complications, and meaningfully improve quality of life. So how does the diagnostic process actually work? It begins with careful observation and moves through a layered set of clinical assessments.

Recognising the early signs
The 7 key assessment and diagnostic methods
1. Blood tests for creatine kinase (CK)
2. Genetic testing
3. Muscle biopsy
4. Electromyography (EMG)
5. Exercise assessments
6. Heart testing – ECG and echocardiogram
7. Imaging tests – MRI and ultrasound
Why a multidisciplinary approach matters

Recognising the early signs

Diagnosis often starts not in a clinic but at home, where parents or caregivers first notice that something is not quite right. Muscular dystrophy is usually diagnosed in children between 3 and 6 years of age, but the warning signs can appear well before that window.

For the most common form – Duchenne muscular dystrophy (DMD) – the average age of diagnosis is around 4 years, and delays in early milestones like sitting, walking, and talking are often the first indicators. Symptoms typically become more apparent between ages 3 and 5, when children may fall more frequently than expected for their age.

Beyond delayed milestones, clinicians and families look out for a distinct cluster of physical signs:

Gowers’ sign: Children with DMD find it very difficult to rise from a sitting or lying position on the floor. They first move to their hands and knees, then walk their hands up their thighs to push themselves upright – a movement pattern known as Gowers’ sign.
Waddling gait and toe-walking: Children may exhibit toe-walking, a waddling gait, or both, as they compensate for weakened muscles.
Pseudohypertrophy of the calves: Doctors may find unexpectedly large calf muscles that are not stronger – a feature called pseudohypertrophy, where damaged muscle tissue is progressively replaced by fat and connective tissue.
Spinal curvature: An arched lower back (lumbar lordosis) and later scoliosis can develop as the muscles supporting the spine weaken.
Difficulty with stairs and falls: Children may have difficulty walking up and down stairs and standing up from the floor, and may appear to “waddle” when they walk.

It is worth noting that diagnosing MD can be challenging because there are more than 30 types that vary in how and when symptoms manifest, and this complexity can lead to substantial diagnostic delays. Recognising these physical patterns early is the first, critical step.

The 7 key assessment and diagnostic methods

Once MD is clinically suspected, a series of specialised tests is used to confirm the diagnosis, identify the specific type, and guide treatment decisions. These tests are based on the type of muscular dystrophy suspected and typically involve a combination of blood work, imaging, electrical studies, and tissue analysis.

1. Blood tests for creatine kinase (CK)

Blood testing is almost always among the first steps. A doctor may order a blood test that can detect elevated levels of creatine kinase (CK), an enzyme released into the bloodstream when muscle fibers deteriorate. Elevated CK levels signal that muscle tissue is being damaged – a red flag that prompts further investigation. The NICHD notes that serum creatine kinase is among the key substances measured, and levels can be dramatically raised – sometimes 10 to 100 times the normal range – in early DMD. Importantly, blood tests can support but cannot alone establish a diagnosis, since elevated CK can also occur in other muscle conditions.

It is also worth knowing that some liver enzymes, notably AST and ALT, can be elevated in muscular dystrophies because these enzymes also exist in muscle and are released during muscle injury – not because of liver damage. This is a common source of initial confusion in diagnosis.

2. Genetic testing

Genetic testing has become the cornerstone of modern MD diagnosis. This type of medical testing identifies changes in a person’s chromosomes, genes, or proteins, and the results can confirm or rule out a diagnosis of muscular dystrophy. A blood draw is the most common method, though cheek swabs, skin biopsies, or muscle biopsies can also be used.

For Duchenne specifically, genetic analysis is first directed to find large deletion or duplication mutations, which account for 70% to 80% of DMD cases. Confirming a mutation in the DMD gene is sufficient to establish a diagnosis. Beyond diagnosis, the specific mutation identified also determines a person’s eligibility for mutation-specific treatments or clinical trials – making genetic precision critically important. The benefits of genetic testing include confirming the diagnosis, identifying specific mutations for targeted treatment, facilitating carrier testing in female relatives, and potentially avoiding unnecessary muscle biopsies.

3. Muscle biopsy

A muscle biopsy is a surgical procedure performed using anaesthesia in which the doctor removes a small piece of affected muscle tissue. Examination of the sample helps distinguish MD from other inflammatory disorders and can identify which specific type of MD is present. Modern techniques can use the biopsy to distinguish muscular dystrophies from inflammatory and other disorders and to distinguish among different forms of the condition.

While muscle biopsy used to be a routine first-line test, it is now rarely indicated because of the wealth of information that genetic testing provides. It remains valuable in ambiguous clinical situations where genetic results are inconclusive.

4. Electromyography (EMG)

Electromyography (EMG) tests how the nerves and muscles work together by measuring electrical impulses along nerves, nerve roots, and muscle tissue. During the test, a tiny needle electrode is inserted through the skin and into the muscle, measuring the electrical activity generated by muscle cells when they are activated. Changes in the pattern of electrical activity can confirm a muscle disease. EMG is particularly useful for ruling out nerve-related conditions that might mimic MD. The National Institute of Neurological Disorders and Stroke (NINDS) also notes that nerve conduction velocity tests – which measure the speed of electrical signals along nerves – are used alongside EMG to determine whether nerve damage, rather than muscle disease, is the underlying problem.

5. Exercise assessments

Functional assessments measure how the condition affects a person’s physical performance and track changes over time. The six-minute walk test (6MWT) is a standard clinical evaluation that assesses a person’s physical function by testing how far they can walk on a flat, hard surface within six minutes. While not used to confirm a diagnosis on its own, the 6MWT helps gauge endurance, exercise capacity, and – critically – how the condition is progressing or responding to treatment. Exercise assessments also measure a patient’s muscle strength and breathing, and detect any increased rates of certain markers following exercise.

6. Heart testing – ECG and echocardiogram

Because many forms of MD directly affect the heart muscle, cardiac monitoring is an essential part of the diagnostic workup. Tests to monitor the heart, such as electrocardiography (ECG) and echocardiogram, are used to check how well the heart works, especially in people with myotonic muscular dystrophy. In DMD, cardiac monitoring including an ECG and cardiac MRI and echocardiogram is recommended at the time of diagnosis and then annually, since the heart muscle can begin to deteriorate before any outward symptoms of heart trouble appear. Early cardiac monitoring can be life-saving, as heart or respiratory complications are among the leading causes of death associated with advanced MD.

7. Imaging tests – MRI and ultrasound

Muscle imaging has become an increasingly valuable, non-invasive tool in MD assessment. Magnetic resonance imaging (MRI) and ultrasound imaging examine muscle quality and bulk, and measure fatty replacement of muscle tissue – providing a detailed picture of which muscles are affected and how severely. MRI is particularly useful for tracking disease progression over time and for guiding where a muscle biopsy should be taken when one is required. Unlike blood tests or genetic studies, imaging offers a direct visual window into the state of the muscles themselves.

Why a multidisciplinary approach matters

No single test is sufficient on its own. An accurate diagnosis of muscular dystrophy requires integrating findings from clinical examination, laboratory tests, imaging, and genetic analysis. People with muscular dystrophy often need to be monitored throughout life by a team of healthcare professionals – including neurologists, cardiologists, respiratory specialists, physiotherapists, and genetic counsellors. This team-based approach ensures that both the primary muscle condition and its secondary effects on the heart, lungs, and spine are addressed comprehensively.

Families are also encouraged to seek genetic counselling before and after testing. Families may be referred for genetic counselling to help them prepare for and understand their test results, including the implications for other family members who may be carriers of the same mutation.

While there is currently no cure for any form of muscular dystrophy, the landscape of treatment is evolving rapidly – particularly for DMD. Mutation-specific gene therapies and exon-skipping drugs are now available or in advanced clinical trials, and an early and accurate diagnosis is important because it allows patients to start working with their care team on a treatment plan that will improve their long-term outlook and quality of life. The sooner the diagnosis, the sooner meaningful support can begin.

What do you think? If a child’s early motor delays are sometimes dismissed as “just being a late developer,” how can educators and school staff play a more active role in flagging signs that warrant a medical evaluation? And given that genetic testing can now identify MD-causing mutations before significant muscle damage occurs, should routine genetic screening become a standard part of early childhood health checks?

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

References

PDF 📄

Table of Contents

Recognising the early signs 🔗

The 7 key assessment and diagnostic methods 🔗

1. Blood tests for creatine kinase (CK) 🔗

2. Genetic testing 🔗

3. Muscle biopsy 🔗

4. Electromyography (EMG) 🔗

5. Exercise assessments 🔗

6. Heart testing – ECG and echocardiogram 🔗

7. Imaging tests – MRI and ultrasound 🔗

Why a multidisciplinary approach matters 🔗